Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer
The aim of this study is to verify if the addition of enzalutamide to docetaxel is able to improve the disease control in first line CRPC patients.
Prostatic Neoplasms
DRUG: Docetaxel|DRUG: Prednisone|DRUG: Enzalutamide
Rate of patients without progression (according to guideline of Prostate Cancer Clinical Trials Working Group 2 - PCWG2), Rate of patients without progression (according to guideline of Prostate Cancer, 6 months after docetaxel first administration
Rate of objective response according to RECIST criteria, Rate of objective response according to RECIST criteria, 6 months after docetaxel first administration|Rate of biochemical response according to PCWG2, Rate of biochemical response according to PCWG2, 6 months after docetaxel first administration|Kaplan-Meier estimates of progression-free survival, Kaplan-Meier estimates of progression-free survival, 6 months after docetaxel first administration|Kaplan-Meier estimates of overall survival, Kaplan-Meier estimates of overall survival, 6 months after docetaxel first administration|Kaplan-Meier estimates of biochemical progression-free survival, Kaplan-Meier estimates of biochemical progression-free survival, 6 months after docetaxel first administration|Rate of treatment-related mortality, Rate of treatment-related mortality, 6 months after docetaxel first administration|Rate of toxicity-related protocol withdrawal, Rate of toxicity-related protocol withdrawal, 6 months after docetaxel first administration|Scales of brief pain inventory (BPI), Scales of brief pain inventory (BPI, 6 months after docetaxel first administration|Analgesic score, Analgesic score, 6 months after docetaxel first administration|Functional scales and items of FACT - P questionnaire, Functional scales and items of FACT - P questionnaire, 6 months after docetaxel first administration|Type and grade of any adverse reaction to treatment, according to CTC-AE v. 4.03, Type and grade of any adverse reaction to treatment, according to CTC-AE v. 4.03, 6 months after docetaxel first administration
CHEIRON trial is a phase II randomized study comparing docetaxel plus enzalutamide to docetaxel alone as first line for castration resistant prostate cancer.